# CJC-1295 Ipamorelin References: The Cited Literature

> CJC-1295 Ipamorelin references: every study cited across the site, with DOIs and PubMed links — the GHRH analogue, the selective GHRP, and the synergy literature.

Every figure on this site traces to one of these. DOIs and PubMed links included.

## Core literature

The studies behind the **CJC-1295 Ipamorelin** claims on this site, numbered as cited. Single-component pharmacology, the synergy evidence, the class safety synthesis, and the read-across comparator data — each line carries its DOI and PubMed identifier. Where a finding is extrapolated rather than measured for the blend, the body pages say so; these are the sources that *are* measured.

## Most recent additions

The freshest entries in the record (2025–2026): the tesamorelin meta-analysis [7], a gerontology peptide review grouping ipamorelin among non-approved peptides lacking long-term safety data, a 2026 musculoskeletal peptide safety/efficacy appraisal, and a 2025 nano-LC-MS method for detecting GHRH analogues in urine (anti-doping context). These extend, but do not change, the central picture: strong single-component pharmacology, no controlled trial of the fixed combination.

## References

[1] Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[2] Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. https://pubmed.ncbi.nlm.nih.gov/9849822/
[3] Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. https://pubmed.ncbi.nlm.nih.gov/2108187/
[4] Cunha SR, et al. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-82. https://pubmed.ncbi.nlm.nih.gov/12446584/
[5] Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. https://pubmed.ncbi.nlm.nih.gov/15817669/
[6] Sigalos JT, et al. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. https://pubmed.ncbi.nlm.nih.gov/28400207/
[7] Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. https://pubmed.ncbi.nlm.nih.gov/41545261/
[8] Farhy LS, et al. Deterministic construct of amplifying actions of ghrelin on pulsatile growth hormone secretion. Am J Physiol Regul Integr Comp Physiol. 2005;288(6):R1649-63. https://pubmed.ncbi.nlm.nih.gov/15718392/
[9] Devesa J, et al. The Complex World of Regulation of Pituitary Growth Hormone Secretion: The Role of Ghrelin, Klotho, and Nesfatins in It. Front Endocrinol. 2021;12:636403. https://pubmed.ncbi.nlm.nih.gov/33776931/
[10] Norman C, et al. Estradiol regulates GH-releasing peptide's interactions with GH-releasing hormone and somatostatin in postmenopausal women. Eur J Endocrinol. 2014;170:121-9. https://pubmed.ncbi.nlm.nih.gov/24114435/
[11] Fraser GL, et al. Effect of the ghrelin receptor agonist TZP-101 on colonic transit in a rat model of postoperative ileus. Eur J Pharmacol. 2009;604:132-7. https://pubmed.ncbi.nlm.nih.gov/19121631/
[12] Venkova K, et al. Prokinetic effects of a new ghrelin receptor agonist TZP-101 in a rat model of postoperative ileus. Dig Dis Sci. 2007;52:2241-8. https://pubmed.ncbi.nlm.nih.gov/17436082/

---

Two receptors logged on one onyx panel — the supra-additive GH crest read off single-peptide data and the general synergy work, the fixed blend's missing trial left as an empty cell; no clinic behind the console and nothing here dosed, stacked, or sold.